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Abstract
Background
Clinical trials suggest that use of fixed-dose combination therapy (‘polypills’) can improve
adherence to medication and control of risk factors of people at high risk of cardiovascular
disease (CVD) compared to usual care, but cost-effectiveness is unknown.
Objective
To determine whether a polypill is cost-effective compared to usual care and optimal guide-
line-recommended treatment for primary prevention in people already on statins and/or
blood pressure lowering therapy.
Methods
A Markov model was developed to perform a cost-utility analysis with a one year time cycle
and a 10 year time horizon to compare the polypill with usual care and optimal implementa-
tion of NICE Guidelines, using patient level data from a retrospective cross-sectional study.
The model was run for ten age (40 years+) and gender-specific sub-groups on treatment for
raised CVD risk with no history of CVD. Published sources were used to estimate impact of
different treatment strategies on risk of CVD events.
Results
A polypill strategy was potentially cost-effective compared to other strategies for most sub-
groups ranging from dominance to up to £18,811 per QALY depending on patient sub-
group. Optimal implementation of guidelines was most cost-effective for women aged 40–
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49 and men aged 75+. Results were sensitive to polypill cost, and if the annual cost was
less than £150, this approach was cost-effective compared to the other strategies.
Conclusions
For most people already on treatment to modify CVD risk, a polypill strategy may be cost-
effective compared with optimising treatment as per guidelines or their current care, as long
as the polypill cost is sufficiently low.
Introduction
Poor uptake of pharmacotherapy for people at high risk of cardiovascular disease, and lack of
adherence in people who are prescribed drugs, has generated interest in the potential for fixed
dose combination pills (‘polypills’).[1,2] These can bring about important reductions in blood
pressure and LDL cholesterol,[3] and are associated with improved adherence to therapy.
[4,5,6,7] However, despite evidence from trials demonstrating that polypills are largely safe
and effective, [8] availability still remains limited compared with other disease areas [9]. Fur-
thermore, no polypill for prevention of cardiovascular disease is currently licensed for use in
the United Kingdom.
Previous cost-effectiveness analyses of polypills have primarily been concerned with treat-
ment of secondary prevention patients [10,11], or, in primary prevention, comparing their use
to no treatment, rather than to usual care or improved implementation of guidelines.[12,13]
The aim of this study was to estimate the cost-effectiveness of a polypill strategy compared
with current treatment or treatment as per guidelines for primary prevention for patients with
known high cardiovascular risk who are already prescribed statins and/or blood pressure low-
ering therapy.
Methods
A Markov cohort model developed in TreeAge Pro estimated cost-effectiveness of primary
prevention with a polypill strategy compared with i) current therapy and ii) optimal therapy as
per guidelines. The model considered patients aged 40 and over prescribed a statin and / or
blood pressure lowering therapy with no history of cardiovascular disease. The model was run
over a ten year time horizon with a one year cycle.
All patients started healthy and moved to other health states if they suffered stroke, myocar-
dial infarction (MI), angina, heart failure or peripheral vascular disease (PVD) or died. Once a
cardiovascular event occurred, they either died, or remained in this health state and incurred
costs and a reduction in quality of life as assigned to that disease state until death (Fig 1).
Study population
A cross sectional retrospective study of primary care medical records in 19 West Midland gen-
eral practices in England provided data on risk factor profiles and current treatment.[14] Ten
year cardiovascular risk was calculated using an updated Framingham equation.[15,16] The
dataset was subdivided into ten age/gender subgroups (40–49, 50–59, 60–69, 70–74, 75 and
over). Within each sub-group, eight treatment/cardiovascular risk strata were identified (S1
Table) that would be treated differently according to UK National Institute for Health and
Care Excellence (NICE) guidelines.[17,18]
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Treatment strategies
Current treatment for each stratum was characterised by whether a statin was being taken, and
if antihypertensives were being taken, the average number per strata.
The polypill strategy consisted of a pill a day containing a statin (40mg simvastatin) and
three antihypertensives at half-dose (12.5mg hydrochlorothiazide, 5mg lisinopril, 2.5mg amlo-
dipine).[19] As the patients were already taking medication, it was assumed the majority
would take the polypill, with 16% discontinuing it (and therefore no longer incurring the cost
of the polypill) and returning to their original treatment.[20] The polypill strategy was applied
regardless of baseline cardiovascular risk or systolic blood pressure.
Fig 1. Model health states.
https://doi.org/10.1371/journal.pone.0182625.g001
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The guideline strategy assumed optimal treatment as per UK NICE guidelines.[17, 18]
Statin therapy (simvastatin 40mg) was prescribed if cardiovascular risk was 20% or higher,
and antihypertensives if blood pressure was greater than 140/90mm/Hg and cardiovascular
risk was 20% or greater.[17] In those patients already on antihypertensives, it was assumed
that additional drugs would be added in order to reach a target systolic blood pressure of
140mmHg, up to a maximum of three drugs. We estimated the additional number of antihy-
pertensive drugs that would be required using the results of a meta-analysis.[21] For each sub-
group we used the starting systolic blood pressure and the degree of blood pressure lowering
required to determine through linear interpolation how many additional drugs would be
needed.
Impact of treatment
The baseline calculated 10 year cardiovascular risk was assumed to reflect benefit of current
treatment (S1 Table), since the values of blood pressure and cholesterol in these patients
reflected their current use of blood pressure lowering and lipid lowering drugs. For optimal
guideline care, the impact of additional treatments was based on results of meta-analysis of
randomised controlled trials (Table 1).[21, 22] We assumed 85% of people prescribed statins
were fully compliant in taking their medication.[23] For the polypill strategy, treatment
already being received was taken into account. If already on statins, then no additional effect
from statins was applied. If antihypertensives were already being taken, the baseline systolic
blood pressure and average number of drugs taken was used to determine the amount of BP
lowering already being achieved, and what effect switching to three half dose drugs would
have.[21] If switching to the polypill resulted in a lower dose of antihypertensives than current
practice, risk estimates were adjusted accordingly.
Outcomes
Outcomes were measured in cardiovascular events and quality-adjusted life years (QALYs). A
baseline utility value was applied depending upon age and gender.[33] When a cardiovascular
event occurred, the health state value for that event was applied as a multiplier (Table 1). For
consistency with other model-based analyses, utility values for CVD health states were
obtained from previous UK NICE guidelines, where values were obtained through systematic
review [18,34]. No reduction in quality of life was assumed for any drugs.[40]
Gender-specific life tables were used to determine the probability of death at different ages.
[41] The risk of death was adjusted to ensure there was no double counting of cardiovascular
death.[42] There was an increased risk of death once in a cardiovascular event health state.
Costs
Costs assumed a UK NHS and personal social services perspective (Table 1). Polypill costs
comprised: £171 (€192) a year for the pill, an initial GP visit and blood test in the first month,
and an annual practice nurse visit and blood test thereafter. Due to the absence of a UK cost
for a polypill, the cost was assumed to be in line that of an existing secondary prevention poly-
pill (Trinomia1), which has a different composition. The cost was calculated using the mean
of available prices and converted from US$ to UK£. In the current treatment and guideline
strategies, the most commonly prescribed generic antihypertensive in each class (indapamide,
amlodopine, ramipril) and the statin simvastatin were assumed.[35] Patients on antihyperten-
sives were allocated four consultations (mix of GP and practice nurse) per year.[43] Two addi-
tional visits (one GP, one practice nurse) were included for guideline treatment in patients
above target blood pressure.
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Table 1. Summary of model inputs.
Data Sources
Baseline mortality and risk of cardiovascular disease
Probability of stroke (10 years) 0.7–6.2%(age and sex
dependent)
Calculated with Framingham [15,16] and risk factor profile based on
patient level data
Probability of MI (10 years) 1.1–9.4% (age and sex
dependent)
Probability of angina (10 years) 1.5–13.3%(age and sex
dependent)
Probability of heart failure (10 years) 0.4–3.9%(age and sex
dependent)
Probability of PVD (10 years) 0.7–6.2% %(age and sex
dependent)
Assumed distribution of possible CV events within 10 year CV risk
Stroke 16% D’Agostino (2008) [16] Wood (2004) [24]
Myocardial infarction 24%
Angina 34%
Heart failure 10%
PVD 16%
Risk reduction with statins
Stroke 0.80 (95% CI 0.73–0.86) CTT (2005),[22] HPS (2002)[23]
MI, HF, angina 0.72 (95% CI 0.69–0.76) CTT (2005), HPS (2002)
PVD 0.85 (95% CI 0.75–0.95) HPS (2002)
Probability of death from event
Fatal stroke 0.19 Ward (2007)[25]
Fatal MI 0.19–0.36 (Men) Ward (2007)
0.23–0.40 (Women)
Fatal heart failure 0.17 (r = 68, n = 396) Mehta (2009) [26]
SMR after stroke 2.72 (95% CI 2.59–2.85) Bronnum-Hansen (2001) [27]
SMR after MI 2.68 (95% CI 2.48–2.91) Bronnum-Hansen (2001) [28]
SMR after Heart Failure 2.17 (95% CI 1.96–2.41) de Guili (2005) [29]
SMR after Angina 2.19 (95% CI 2.05–2.33) NCGC [30]
SMR after PVD 2.44 (95% CI 1.59–3.74) Leng (1996) [31]
Reduction in blood pressure
Number of AHT drugs required to achieve
target BP
0.60–1.52 Law (2009)[21]
Reduction in CV risk with reduction in BP
Polypill
CHD risk 10–52% Law (2009)
Stroke risk 14–65% Law (2009)
PVD risk 13–23% Murabito (1997)[32]
(Dependent on age, sex and risk
group)
Treat to target
CHD risk 15–37% Law (2009)
Stroke risk 20–47% Law (2009)
PVD risk 13–32% Murabito (1997)
(Dependent on age, sex and risk
group)
Polypill adherence 84% TIPS (2009)[20]
(Continued )
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Analysis
An incremental cost-utility analysis was undertaken with a threshold of £20,000 per QALY
taken to indicate cost-effectiveness. Future costs and QALYs were discounted at 3.5% per
annum.[44] Costs were in UK pounds for 2011/12. Conversion into Euros was via the Pur-
chasing Power Parity (PPP) Index for 2012, using a conversion rate of £1 to €1.125.[45] A half-
cycle correction was applied to costs and effectiveness. We explored the impact of changing
key parameters in a deterministic sensitivity analysis in a single age-sex stratum (men aged
60–69). Analysis of impact of price involved halving and doubling the price of a ‘polypill’ and
reducing the cost to £57 (€64) a year, to reflect cost of individual generic agents.[35] The
threshold price at which a polypill would become cost effective for each sub-group was
Table 1. (Continued)
Data Sources
Utilities
No cardiovascular event (age and sex dependent) General population utilities from EQ-5D (UK Tariff) (NCSR, 2006)[33]
Death 0 By definition
Quality of life multipliers
Acute MI 0.76 (0.018) Cooper (2008)[18], NICE (2014) [34]
Post MI 0.88 (0.018) As above
Acute angina 0.77 (0.038) As above
Post-acute angina 0.88 (0.018) As above
Heart failure 0.68 (0.020) As above
Stroke 0.63 (0.040) As above
PVD 0.90 (0.020) As above
Costs
£ per year
Simvastatin 40mg 15.26 BNF March 2013 [35]
Amlodopine 5mg 12.13 BNF March 2013
Indapamide 2.5mg 11.87 BNF March 2013
Ramipril 5mg 18.13 BNF March 2013
Polypill 171 Assumed same price as Trinomia
Unit cost £
Blood test 15 Ward (2007)
GP visit 33 Curtis (2012) [36]
Practice nurse visit 11.25 Curtis (2012)
Acute events: One-off cost £
Stroke 11,020 Youman (2003) [37]
MI 5,487 Palmer (2002) [38]
Angina 3,292 Assumed 60% of MI cost
PVD 1,971 NHS Reference costs 2011/12 [39]
Heart failure 2,699 NHS Reference costs 2011/12
Long-term costs £ per year
Stroke 2721 Youman (2003)
MI 572 Cooper (2008) [18]
Angina 572 Cooper (2008)
PVD 302 Cooper (2008)
Heart failure 572 Cooper (2008)
SMR: Standardised Mortality Ratio; MI: Myocardial infarction; PVD: Peripheral Vascular Disease; CV: Cardiovascular
https://doi.org/10.1371/journal.pone.0182625.t001
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determined. Where available, data were entered into the model as distributions so that a
probabilistic sensitivity analysis could be undertaken. A log-normal distribution was used for
all risk reductions and standardised mortality ratios after cardiovascular events, a beta distri-
bution for cardiovascular event probabilities, risk of death from cardiovascular events and
compliance with screening and a gamma distribution for acute and long-term costs. A Proba-
bilistic Sensitivity Analysis (PSA) was run with 10,000 simulations and cost-effectiveness
acceptability curves were produced (not shown) to provide information on the probability of
interventions being cost-effective at different cost per QALY thresholds.
Results
In the base-case analysis, the polypill strategy led to fewer CV events and was cost-effective
over current practice and optimal treatment as per guidelines for men aged 50–74 and women
over the age of 50. Subpopulation results varied from the polypill strategy being dominant (i.e.
less costly and more effective), to Incremental Cost Effectiveness Ratios (ICERs) up to £18,811
(€21,162) per QALY gained (Tables 2 and 3). Optimal guideline care was dominant over the
polypill for men aged over the age of 75 (but with very small differences in costs and QALYs),
and most cost-effective in women aged 40–49.
The probabilistic sensitivity analysis for all three treatment options showed that the polypill
had a high probability (over 90%) of being cost-effective at a £20,000 (€22,500)/QALY thresh-
old for men except for the youngest and oldest sub-groups. There was much more uncertainty
in the results for women, with only the 60–69 and 70–74 sub-groups having a high probability
of the polypill being the most cost-effective option. with considerable uncertainty around the
results for those aged 50–59 (54% probability of being the most cost-effective option at
£20,000/QALY). (Tables 2 and 3).
Deterministic sensitivity analyses for men aged 60–69 demonstrated that the superior cost
effectiveness of a polypill over optimal guideline care over was robust to some underlying
assumptions made in the model, with some key exceptions. Optimal guidelines became the
most favourable strategy if take up of a polypill was low, if polypill was associated with a small
reduction in quality of life, if polypill was less effective than assumed, and if the population was
restricted to those with uncontrolled risk factors only (Table 4). The results were particularly
sensitive to the cost of the polypill, with dominance achieved by halving the price or further
reducing to the cost of the individual components. The superiority of the polypill compared
with current practice in men aged 60–69 was sensitive to the cost of polypill, but robust to
changes to the other assumptions (Table 5). Threshold analysis showed that the annual price
of the polypill would need to be £152 (€171) or less to ensure cost-effectiveness at the £20,000
(€22,500)/QALY threshold for all sub-groups when compared with guidelines (Table 6).
Discussion
Our base-case analysis suggests that using a polypill is more cost effective than usual practice
for all age groups over 40 years apart from 40–49 year old women. The polypill is also cost-
effective compared with optimal implementation of guidelines for most age and sex strata.
Probabilistic sensitivity analysis showed that the superiority of polypill over usual care was
very unlikely to be a chance finding, but there was more uncertainty over the comparison with
optimal implementation of guidelines. This pattern was reflected in the deterministic sensitiv-
ity analysis which found that the superiority of polypill over usual care was robust to changing
our assumptions, but not in comparison to optimal implementation of guidelines.
Switching to a polypill strategy may be a more cost effective way of improving cardiovascular
prevention in people on treatment for raised cardiovascular risk than current practice or better
Economic evaluation of a polypill for CVD prevention
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implementation of guidelines in most patient sub-groups. However, this result was highly sensi-
tive to cost of a polypill, take up of this treatment and potential effectiveness in reducing CV risk.
At current individual drug prices, if a polypill cost £150 (€169) per year (i.e. a cost of 41p (€0.46)
per pill), a polypill would be more cost effective than achieving optimal guideline care for all peo-
ple over the age of 40 who are on treatment. Given that the costs of prescribing the individual
components of the polypill are only around £57 (€64) per annum, this seems a feasible price not
withstanding any technical difficulties of combining components in a single pill.
Previous cost effectiveness analyses have focussed on cost effectiveness of a polypill against
no treatment, and found that this it is likely to be cost effective for primary prevention of high
risk individuals in the developing world.[12, 13, 46]
Trials of using a polypill compared to usual care in people at high risk of cardiovascular dis-
ease have found better self-reported use of medication in the polypill arm,[5,6,7] and in one
trial, this was also associated with better control of risk factors.[5] None of these trials included
any intervention to enhance usual care.
The results need to be interpreted in the light of certain limitations. In a number of respects,
the cost effectiveness of a polypill may have been under-estimated. The analysis was restricted
Table 2. Results of the base-case analysis and probabilistic sensitivity analysis: Men.
Age
group
Strategy Mean
cost (£)
Mean
QALYs
Mean CV
events
Incremental
cost
Incremental
QALYs
ICER (£ per
QALY gained)
Probability of cost-
effectiveness at £20,000/
QALY
Polypill vs
current
practice
ICER(£ per
QALY gained)
40–49 Current
practice
1,625 7.202 0.0956 0 0 - 0%
Optimal
guideline
care
1,634 7.216 0.0822 8 0.014 604 41%
Polypill 1,878 7.229 0.0683 244 0.014 18,057 59% 9,166
50–59 Current
practice
2,008 6.740 0.1499 0 0 - 0%
Optimal
guideline
care
2,013 6.765 0.1290 5 0.025 182 0%
Polypill 2,136 6.784 0.1119 123 0.019 6,466 100% 2,897
60–69 Optimal
guideline
care
2,315 6.524 0.1714 0 0 - 0%
Current
practice
2,343 6.477 0.2064 28 -0.047 Dominated 0%
Polypill 2,386 6.539 0.1592 71 0.015 4,791 100% 698
70–74 Optimal
guideline
care
2,429 5.916 0.1890 0 0 - 9%
Current
practice
2,457 5.853 0.2334 28 -0.063 Dominated 0%
Polypill 2,459 5.922 0.1861 31 0.006 5,068 91% 33
Optimal
guideline
care
2,320 4.782 0.1988 0 0 - 69%
Polypill 2,327 4.781 0.2005 7 -0.001 Dominated 31% Dominant
75+ Current
practice
2,395 4.692 0.2564 68 -0.089 Dominated 0%
https://doi.org/10.1371/journal.pone.0182625.t002
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to higher risk people already on treatment–inclusion of people not on medication would have
increased the cost-effectiveness of polypill relative to current practice. Potential benefits of
improved adherence to a polypill were not included.[5] It was assumed that 100% achievement
of guideline targets is possible and indeed desirable.[47] However, this has probably not had a
significant impact on overall results, since blood pressure target trials tend to show that mean
blood pressure for the study population is below target, even if a substantial proportion of indi-
viduals have final blood pressure above target.[43,48,49] Thus, the impact of blood pressure
lowering will have been over-estimated in some patients and under-estimated in others in the
optimal implementation of guidelines strategy. The base-case analysis considered a 10-year
time horizon as opposed to a life time horizon (which our sensitivity analysis showed tends to
favour the polypill). This limited time horizon was chosen because of the complexities of esti-
mating changes in risk factors (and therefore cardiovascular risk) over time. Finally, the risk of
further events once someone had an initial cardiovascular event was not modelled, so potential
benefits of treatments of secondary prevention were ignored.
Conversely, other assumptions favoured polypill. The separate drugs in the polypill were
assumed to have additive effects. While one trial did find additive effects,[50] others have
Table 3. Results of the base-case analysis and probabilistic sensitivity analysis: Women.
Age
group
Strategy Mean
cost (£)
Mean
QALYs
Mean CV
events
Incremental
cost
Incremental
QALYs
ICER (£ per
QALY
gained)
Probability of cost-
effectiveness at £20,000/
QALY
Polypill vs
current
practice
ICER (£ per
QALY gained)
40–49 Current
practice
1,325 7.077 0.0505 0 0 - 0%
Optimal
guideline
care
1,343 7.083 0.0446 18 0.006 2,994 94%
Polypill 1,671 7.093 0.0354 328 0.010 33,585 6% 21,798
50–59 Current
practice
1,586 6.675 0.0894 0 0 - 0%
Optimal
guideline
care
1,599 6.688 0.0770 13 0.013 950 46%
Polypill 1,841 6.701 0.0644 243 0.013 18,811 54% 9,696
60–69 Current
practice
1,805 6.513 0.1203 0 0 - 0%
Optimal
guideline
care
1,829 6.530 0.1060 23 0.018 1,304 2%
Polypill 1,994 6.546 0.0928 165 0.015 10,730 98% 5,667
70–74 Current
practice
1,985 5.982 0.1492 0 0 - 0%
Optimal
guideline
care
2,042 6.009 0.1281 57 0.027 2,105 0%
Polypill 2,097 6.022 0.1170 55 0.013 4,245 100% 2,797
75+ Current
practice
1,880 4.733 0.1644 0 0 - 0%
Optimal
guideline
care
1,947 4.774 0.1345 66 0.041 1,606 63%
Polypill 1,967 4.779 0.1303 20 0.005 4,131 37% 1,870
https://doi.org/10.1371/journal.pone.0182625.t003
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reported smaller combined effects.[3] The polypill was assumed to have no adverse effects on
quality of life–sensitivity analysis showed that a small shift in this assumption would favour
current practice. However, there is no empirical evidence of differences in quality of life
between people on the polypill or usual care.[5] Optimal guideline care was based on guide-
lines in force in the UK up until 2014. Recent NICE guidelines have lowered the 10 year risk
threshold for statin treatment from 20% to 10%.[34] This would result in a higher proportion
of the study population being treated with statins in the optimal guideline implementation.
This would have little effect on older age groups (see Table 1), but would result in increased
effectiveness (and cost) of optimal guideline care in younger age groups. Finally, there are sev-
eral other potential formulations of a polypill, which might have different effects on cardiovas-
cular risk factors.[3]
Conclusions
This analysis suggests that a polypill strategy may be a cost effective means to improve primary
prevention in most people aged 50 and over with high cardiovascular risk on treatment, as
Table 4. Deterministic sensitivity analysis results (men aged 60–69) for polypill strategy vs optimal guideline care.
Cost difference vs.
guidelines(£)
QALY difference vs.
guidelines
Most CE strategy* and ICER
(£/QALY) for polypill
Base case 71 0.015 Polypill (£4,791)
Sensitivity analysis
Cost of polypill doubled 342 0.015 Guidelines (£76,849)
Cost of polypill halved -462 0.015 Polypill dominates
Cost of polypill reduced to £57/year -640 0.015 Polypill dominates
Decreased take up of polypill (25% take polypill) 95 -0.029 Guidelines dominates
Change cost of CV events
increase by 30% 45 0.015 Polypill (£3,030)
decrease by 30% 97 0.015 Polypill (£6,553)
Quality of life reduction with polypill by 1% 71 -0.037 Guidelines dominates
Reduction in polypill effectiveness
Antihypertensive effect reduced (statin effect fixed):
50% 180 -0.004 Guidelines dominates
25% 126 0.006 Guidelines (£22,500)
Statins effect reduced (antihypertensive effect fixed) by
25%
95 0.010 Polypill (£9,397)
Antihypertensive and statin effect reduced by 25% 151 0.001 Guidelines (£228,788)
Increase costs of achieving optimal guideline care‡ -582 0.015 Polypill dominates
Study population restricted to people with uncontrolled
risk factors at baseline†
-51 - 0.013 Guidelines (£3,952)**
Baseline CVD risk reduced by 30% 97 0.011 Polypill (£9,110)
Alternative time horizon
20 years 49 0.048 Polypill (£1,011)
30 years 42 0.078 Polypill (£546)
Lifetime 40 0.084 Polypill (£473)
* CE at a £20,000/QALY gained threshold
** ICER is in the south-west quadrant and polypill is not CE as it is <£20,000/QALY
† i.e.20% ten year cardiovascular risk and not on a statin, and/or with systolic blood pressure > 140 mmHg
‡ 4 additional (2 GP and 2 practice nurse) consultations per year over usual care, rather than 2 (1 of each).
https://doi.org/10.1371/journal.pone.0182625.t004
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Table 5. Deterministic sensitivity analysis results (men aged 60–69) for polypill strategy vs current practice.
Cost difference vs. current
practice
QALY difference vs. current
practice
Most CE strategy* and ICER
for polypill
Base case 43 0.062 Polypill (£698)
Sensitivity analysis
Cost of polypill doubled 1,100 0.062 Polypill (£18,045)
Cost of polypill halved -490 0.062 Polypill dominates
Cost of polypill reduced £57/year -668 0.062 Polypill dominates
Decreased take up of polypill (25% take polypill) 67 0.018 Polypill (£3,702)
Change cost of CV events.
CV events increase by 30% -67 0.062 Polypill dominates
CV events decrease by 30% 153 0.062 Polypill (£2.490)
Quality of life reduction with polypill by 1% 43 0.001 Polypill (£4,475)
Reduction in polypill effectiveness
Antihypertensive effect reduced (statin effect fixed)
50% 152 0.043 Polypill (£3,517)
25% 98 0.052 Polypill (£1,865)
Statins effect reduced (antihypertensive effect fixed) by
25%
66 0.057 Polypill (£1,169)
Antihypertensive and statin effect reduced by 25% 122 0.047 Polypill (£2,582)
Study population restricted to people with uncontrolled
risk factors at baseline†
-102 0.081 Polypill dominates
Baseline CVD risk reduced by 30% 143 0.045 Polypill (£3,206)
Alternative time horizon
20 years -5 0.190 Polypill dominates
30 years 12 0.293 Polypill (£40)
Lifetime 16 0.315 Polypill (£50)
* CE at a £20,000/QALY gained threshold
† i.e. >20% ten year cardiovascular risk and not on a statin, and/or with systolic blood pressure > 140 mmHg
https://doi.org/10.1371/journal.pone.0182625.t005
Table 6. Optimal price of polypill.
Subgroup Annual cost of polypill where the polypill is
CE vs optimal guideline care (£)
Annual cost of polypill where the polypill
is CE vs current practice (£)
Male
40–49 175 215
50–59 210 285
60–69 207 361
70–74 187 408
75+ 165 542
Female
40–49 152 167
50–59 173 211
60–69 193 244
70–74 204 282
75+ 185 324
(CE = <£20,000/QALY gained),. Base case price £365.25
https://doi.org/10.1371/journal.pone.0182625.t006
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long as the cost of a polypill is sufficiently low. If the cost of a polypill is lower than £150
(€169) per year, then this approach becomes cost effective for all sub-groups. However, despite
the growing evidence base of the effectiveness of polypills,[3,5] such combinations are not yet
generally available. This perhaps in part reflects reluctance of pharmaceutical companies to
invest in multi-component pills and the hurdles posed by regulatory approval.[51] At the right
price, a polypill strategy could be the most cost effective way of ensuring optimal cardiovascu-
lar risk reduction in people who are on treatment with antihypertensives or lipid lowering
agents to lower their cardiovascular risk.
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